TY - CHAP
T1 - CAR T-Cells
AU - Nair, Ranjit
AU - Westin, Jason
PY - 2020
Y1 - 2020
N2 - CAR-T (chimeric antigens receptor-T) cell therapy is a breakthrough therapy of the twenty-first century for the management of different malignancies including lymphomas and leukemias. Numeral trials are underway to understand the optimal CAR-T cell design and dose to maximize efficacy and mitigate toxicity. Currently two CAR-T cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, are approved by the US Food and Drug Administration, which have shown excellent responses in otherwise poor prognostic lymphomas and leukemias. The favorable outcomes achieved of this therapy were noted to be durable during long-term follow-up. Understanding the challenges associated with manufacturing and the reasons for T cell failure including poor T cell expansion, persistence, and tumor resistance are critical for its wide-scale application in order to attain the full potential of this novel therapy. Here we review the salient features of the different CAR-T products and discuss the pivotal trials that led to its approval.
AB - CAR-T (chimeric antigens receptor-T) cell therapy is a breakthrough therapy of the twenty-first century for the management of different malignancies including lymphomas and leukemias. Numeral trials are underway to understand the optimal CAR-T cell design and dose to maximize efficacy and mitigate toxicity. Currently two CAR-T cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, are approved by the US Food and Drug Administration, which have shown excellent responses in otherwise poor prognostic lymphomas and leukemias. The favorable outcomes achieved of this therapy were noted to be durable during long-term follow-up. Understanding the challenges associated with manufacturing and the reasons for T cell failure including poor T cell expansion, persistence, and tumor resistance are critical for its wide-scale application in order to attain the full potential of this novel therapy. Here we review the salient features of the different CAR-T products and discuss the pivotal trials that led to its approval.
KW - Acute lymphoblastic leukemia
KW - Axicabtagene ciloleucel
KW - CAR T-cell
KW - Cytokine-release syndrome
KW - Diffuse large B-cell lymphoma
KW - Follicular lymphoma
KW - Immune effector cell-associated neurotoxicity syndrome
KW - Immunotherapy
KW - Lisocabtagene maraleucel
KW - Siltuximab
KW - Tisagenlecleucel
KW - Tocilizumab
UR - http://www.scopus.com/inward/record.url?scp=85083631793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083631793&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-41008-7_10
DO - 10.1007/978-3-030-41008-7_10
M3 - Chapter
C2 - 32301017
AN - SCOPUS:85083631793
T3 - Advances in Experimental Medicine and Biology
SP - 215
EP - 233
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -